Clinical data investigation identifies MARK3 as an oncogenic driver in castration-resistant prostate cancer
Castration-resistant prostate cancer (CRPC) represents an aggressive and fatal form of prostate cancer that emerges following resistance to androgen deprivation therapy. Despite the availability of various drugs that can enhance the quality and prolong the survival of CRPC patients, resistance to th...
Saved in:
| Main Authors: | Rajnikant Raut, Devesh Srivastava, Vinayak Nayak, Taruna Saini, Parth Gupta, Amit Kumar Chakraborty, Chumki Choudhury, Manish V. Bais, Parul Mishra, Ashish Misra |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Biochemistry and Biophysics Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2405580825000901 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Integrative analysis identifies FBXO5 as a critical mediator of CRPC progression and bone metastatic potential
by: Rajnikant Raut, et al.
Published: (2025-08-01) -
Insulin‐Like Growth Factor 2 mRNA‐Binding Protein 2 (IGF2BP2) Promotes Castration‐Resistant Prostate Cancer Progression by Regulating AR‐V7 mRNA Stability
by: Taruna Saini, et al.
Published: (2025-02-01) -
Sequential therapy with darolutamide in patients with non‐metastatic castration‐resistant prostate cancer resistant to enzalutamide or apalutamide
by: Saizo Fujmoto, et al.
Published: (2023-02-01) -
MBsNRP2-based ultrasound molecular imaging for early diagnosis of castration-resistant prostate cancer
by: Na Wang, et al.
Published: (2025-04-01) -
Impact of interdisciplinary tumor boards (ITB) and personalized treatment on survival outcomes in metastatic castration-resistant prostate cancer
by: Laura Lawaczeck, et al.
Published: (2025-03-01)